To assess the impact of tamoxifen on development of breast cancer, coronary heart disease,
and bone fractures. The National Cancer Institute initiated the prevention trial under its
National Surgical Adjuvant Breast and Bowel Project (NSABP). The National Heart, Lung, and
Blood Institute provided support to obtain blood pressure and lipid measurements, and
lipoprotein and selected coagulation factor measurements in a subsample.